Dag Nyholm

Has grant

Professor of Neurology

Uppsala University

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dag Nyholm is a Professor of Neurology at Uppsala Universitet in Sweden. His research focuses on advanced therapies for Parkinson's disease, including pharmacological interventions and cost-effectiveness analyses. He has authored several recent articles investigating the efficacy of various treatment modalities and the impact of COVID-19 on patients with Parkinson's disease. Dr. Nyholm is also exploring novel biomarkers for neurodegenerative disorders.

Recent Grants

Grant: Close

Patient-specific dynamical modeling and optimization of Deep Brain Stimulation

Open Date: 2021-01-01

Close Date: 2023-12-31

Grant: Close

Individualization of levodopa infusion through objective symptom quantification

Open Date: 2019-05-01

Close Date: 2020-09-30

Grant: Close

Treatment of late stages of Parkinson´s disease with a highly concentrated DOPA solution administered subcutaneously or intravenously ? a national, multicenter, academia-based trial

Open Date: 2014-01-01

Close Date: 2017-12-31

Grant: Close

A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson´s disease

Open Date: 2013-01-01

Close Date: 2015-12-31

Grant: Close

Randomization of patients with Advanced Parkinson´s disease to intestinal levodopa/carbidopa Infusion or bilateral Deep brain stimulation of the subthalamic nucleus (Acronym: RAPID)

Open Date: 2012-01-01

Close Date: 2014-12-31

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Per Svenningsson

King’s College London

UNITED KINGDOM

View details

Mezin Öthman

Uppsala University

SWEDEN

View details

Mevludin Memedi

Senior Lecturer

Örebro university

SWEDEN

View details

Thomas Sahlström

Lund University

SWEDEN

View details

Ioanna Markaki

Karolinska Institutet

SWEDEN

View details

Per Odin

Lund University

SWEDEN

View details

Ilir Jusufi

Blekinge Institute of Technology

SWEDEN

View details

Gunnar O Klein

Örebro Universitet Handelshögskolan

SWEDEN

View details

Nil Dizdar

department of biomedical and clinical sciences linköping university linköping sweden

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dag Nyholm

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease

COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion

NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy

Therapies for Advanced Parkinson’s Disease in Sweden: A Cost-Effectiveness Analysis Using Real-World Data

Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion.

“I’m still the person I am. Not the body it has become.” An active but challenging life with cervical dystonia

Comparison of quantitative [11C]PE2I brain PET studies between an integrated PET/MR and a stand-alone PET system

A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease

The Impact of COVID-19 on Parkinson’s Disease: A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients’ Perceptions

Phosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy

Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System

Attitudes and values among the Swedish general public to using human embryonic stem cells for medical treatment

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease

Composite attenuation correction method using a 68Ge-transmission multi-atlas for quantitative brain PET/MR

Optimizing Treatment of Parkinson’s Disease

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice

Imaging features associated with idiopathic normal pressure hydrocephalus have high specificity even when comparing with vascular dementia and atypical parkinsonism.

Close relationships in Parkinson´s disease patients with device‐aided therapy

Collaborators (9)

Per Svenningsson

Mezin Öthman

Mevludin Memedi

Thomas Sahlström

Ioanna Markaki

Per Odin

Ilir Jusufi

Gunnar O Klein

Nil Dizdar

Make your next move.